대변 항원 검사 시장 규모, 점유율, 동향 분석 보고서 : 검사 유형별, 기술별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Stool Antigen Testing Market Summary

The global stool antigen testing market size was valued at USD 679.11 million in 2025 and is projected to grow from USD 762.17 million in 2026 to USD 1334.23 million by 2033, at a CAGR of 8.33% from 2026 to 2033. The North America stool antigen testing market held the largest share of 39.76% of the global market in 2025, due to the rising prevalence of gastrointestinal infections such as H. pylori and diarrheal diseases, which require accurate and early diagnosis.

Furthermore, growth is also supported by improvements in testing technologies such as ELISA and rapid immunoassays.

Global Stool Antigen Testing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global stool antigen testing market report based on test type, technology, application, end use, and region.

• Test Type Outlook (Revenue, USD Million, 2021 - 2033)
• Bacterial Antigen test
• Viral Antigen Tests
• Parasitic Antigen Tests
• Multiplex/Combination Stool Antigen Panels
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Lateral Flow Immunoassays (Rapid Tests)
• Immunochromatography Assays
• Fluorescent Immunoassays
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Gastrointestinal Infection Diagnosis
• Helicobacter pylori Detection
• Diarrheal Disease Diagnosis
• Parasitic Infection Screening
• Hospital-Acquired Infection Monitoring
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Diagnostic Laboratories
• Academic & Research Institutes
• Ambulatory Care Centers
• Home/point-of-care testing settings
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Test Type Segment
    • 1.1.1.2. Application Segment
    • 1.1.1.3. Technology Segment
    • 1.1.1.4. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
  • 1.3.1. Objectives
  • 1.3.2. Objective - 1
  • 1.3.3. Objective - 2
  • 1.3.4. Objective - 3
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information or Data Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Validation
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Test Type & Technology Snapshot
• 2.3. Application & End Use Snapshot
• 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising prevalence of gastrointestinal infections and digestive disorders Advancements in imaging techniques and increasing affordability of diagnostics
    • 3.2.1.2. Growing preference for non-invasive diagnostic methods
    • 3.2.1.3. Advancements in diagnostic technologies and point-of-care testing
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Limited accuracy and the risk of false results
    • 3.2.2.2. Lack of awareness and limited access in developing regions
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis

Chapter 4. Test Type Business Analysis

• 4.1. Stool Antigen Testing Market: Test Type Movement Analysis
• 4.2. Bacterial Antigen Test
  • 4.2.1. Bacterial Antigen Test Market, 2021 - 2033 (USD Million)
• 4.3. Viral Antigen Test
  • 4.3.1. Viral Antigen Test Market, 2021 - 2033 (USD Million)
• 4.4. Parasitic Antigen Test
  • 4.4.1. Parasitic Antigen Test Market, 2021 - 2033 (USD Million)
• 4.5. Multiplex/Combination Stool Test
  • 4.5.1. Multiplex/Combination Stool Test Market, 2021 - 2033 (USD Million)

Chapter 5. Technology Business Analysis

• 5.1. Stool Antigen Testing Market: Technology Movement Analysis
• 5.2. Enzyme-Linked Immunosorbent Assay (ELISA)
  • 5.2.1. Enzyme-Linked Immunosorbent Assay (ELISA) Market, 2021 - 2033 (USD Million)
• 5.3. Lateral Flow Immunoassays (Rapid Tests)
  • 5.3.1. Lateral Flow Immunoassays (Rapid Tests) Market, 2021 - 2033 (USD Million)
• 5.4. Immunochromatography Assays
  • 5.4.1. Immunochromatography Assays Market, 2021 - 2033 (USD Million)
• 5.5. Fluorescent Immunoassays
  • 5.5.1. Fluorescent Immunoassays Market, 2021 - 2033 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. Stool Antigen Testing Market: Application Movement Analysis
• 6.2. Gastrointestinal Infection Diagnosis
  • 6.2.1. Gastrointestinal Infection Diagnosis Market, 2021 - 2033 (USD Million)
• 6.3. Helicobacter pylori Detection
  • 6.3.1. Helicobacter pylori Detection Market, 2021 - 2033 (USD Million)
• 6.4. Diarrheal Disease Diagnosis
  • 6.4.1. Diarrheal Disease Diagnosis Market, 2021 - 2033 (USD Million)
• 6.5. Parasitic Infection Screening
  • 6.5.1. Parasitic Infection Screening Market, 2021 - 2033 (USD Million)
• 6.6. Hospital-Acquired Infection Monitoring
  • 6.6.1. Hospital-Acquired Infection Monitoring Market, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

• 7.1. Hospitals & Clinics
  • 7.1.1. Hospitals & Clinics Market, 2021 - 2033 (USD Million)
• 7.2. Diagnostic Laboratories
  • 7.2.1. Diagnostic Laboratories Market, 2021 - 2033 (USD Million)
• 7.3. Home/point-of-care testing settings
  • 7.3.1. Home/point-of-care testing settings Market, 2021 - 2033 (USD Million)
• 7.4. Academic & Research Institutes
  • 7.4.1. Academic & Research Institutes Market, 2021 - 2033 (USD Million)
• 7.5. Ambulatory Care Centers
  • 7.5.1. Ambulatory Care Centers Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Stool Antigen Testing Market Share By Region, 2025 & 2033
• 8.2. North America
  • 8.2.1. SWOT Analysis
  • 8.2.2. North America Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.2.3. U.S.
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Target Disease Prevalence
    • 8.2.3.3. Competitive Scenario
    • 8.2.3.4. Regulatory Framework
    • 8.2.3.5. U.S. Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.2.4. Mexico
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Target Disease Prevalence
    • 8.2.4.3. Competitive Scenario
    • 8.2.4.4. Regulatory Framework
    • 8.2.4.5. Mexico Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.2.5. Canada
    • 8.2.5.1. Key Country Dynamics
    • 8.2.5.2. Target Disease Prevalence
    • 8.2.5.3. Competitive Scenario
    • 8.2.5.4. Regulatory Framework
    • 8.2.5.5. Canada Stool Antigen Testing Market, 2021 - 2033 (USD Million)
• 8.3. Europe
  • 8.3.1. SWOT Analysis
  • 8.3.2. Europe Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.3.3. UK
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Target Disease Prevalence
    • 8.3.3.3. Competitive Scenario
    • 8.3.3.4. Regulatory Framework
    • 8.3.3.5. UK Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.3.4. Germany
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Target Disease Prevalence
    • 8.3.4.3. Competitive Scenario
    • 8.3.4.4. Regulatory Framework
    • 8.3.4.5. Germany Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.3.5. Spain
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Target Disease Prevalence
    • 8.3.5.3. Competitive Scenario
    • 8.3.5.4. Regulatory Framework
    • 8.3.5.5. Spain Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.3.6. France
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Target Disease Prevalence
    • 8.3.6.3. Competitive Scenario
    • 8.3.6.4. Regulatory Framework
    • 8.3.6.5. France Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.3.7. Italy
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Target Disease Prevalence
    • 8.3.7.3. Competitive Scenario
    • 8.3.7.4. Regulatory Framework
    • 8.3.7.5. Italy Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.3.8. Denmark
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Target Disease Prevalence
    • 8.3.8.3. Competitive Scenario
    • 8.3.8.4. Regulatory Framework
    • 8.3.8.5. Denmark Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.3.9. Sweden
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Target Disease Prevalence
    • 8.3.9.3. Competitive Scenario
    • 8.3.9.4. Regulatory Framework
    • 8.3.9.5. Sweden Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.3.10. Norway
    • 8.3.10.1. Key Country Dynamics
    • 8.3.10.2. Target Disease Prevalence
    • 8.3.10.3. Competitive Scenario
    • 8.3.10.4. Regulatory Framework
    • 8.3.10.5. Norway Stool Antigen Testing Market, 2021 - 2033 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. SWOT Analysis
  • 8.4.2. Asia Pacific Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.4.3. Japan
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Competitive Scenario
    • 8.4.3.4. Regulatory Framework
    • 8.4.3.5. Japan Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.4.4. China
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Competitive Scenario
    • 8.4.4.4. Regulatory Framework
    • 8.4.4.5. China Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.4.5. India
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Target Disease Prevalence
    • 8.4.5.3. Competitive Scenario
    • 8.4.5.4. Regulatory Framework
    • 8.4.5.5. India Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.4.6. South Korea
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Target Disease Prevalence
    • 8.4.6.3. Competitive Scenario
    • 8.4.6.4. Regulatory Framework
    • 8.4.6.5. South Korea Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.4.7. Australia
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Target Disease Prevalence
    • 8.4.7.3. Competitive Scenario
    • 8.4.7.4. Regulatory Framework
    • 8.4.7.5. Australia Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.4.8. Thailand
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Target Disease Prevalence
    • 8.4.8.3. Competitive Scenario
    • 8.4.8.4. Regulatory Framework
    • 8.4.8.5. Thailand Stool Antigen Testing Market, 2021 - 2033 (USD Million)
• 8.5. Latin America
  • 8.5.1. SWOT Analysis
  • 8.5.2. Latin America Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.5.3. Brazil
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. Regulatory Framework
    • 8.5.3.5. Brazil Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.5.4. Argentina
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Competitive Scenario
    • 8.5.4.4. Regulatory Framework
    • 8.5.4.5. Argentina Stool Antigen Testing Market, 2021 - 2033 (USD Million)
• 8.6. MEA
  • 8.6.1. SWOT Analysis
  • 8.6.2. MEA Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.6.3. South Africa
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Competitive Scenario
    • 8.6.3.4. Regulatory Framework
    • 8.6.3.5. South Africa Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Competitive Scenario
    • 8.6.4.4. Regulatory Framework
    • 8.6.4.5. UAE Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.6.5. Saudi Arabia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Competitive Scenario
    • 8.6.5.4. Regulatory Framework
    • 8.6.5.5. Saudi Arabia Stool Antigen Testing Market, 2021 - 2033 (USD Million)
  • 8.6.6. Kuwait
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Competitive Scenario
    • 8.6.6.4. Regulatory Framework
    • 8.6.6.5. Kuwait Stool Antigen Testing Market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Share Analysis, 2022
• 9.4. Company Profiles/Listing
  • 9.4.1. Abbott
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.1.3. Technology Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. BIOMERIEUX
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.2.3. Technology Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Thermo Fisher Scientific Inc
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.3.3. Technology Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. F. Hoffmann- La Roche Ltd.
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.4.3. Technology Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Meridian Biosience, Inc.
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.5.3. Technology Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Danaher Corporation (Beckman Coulter)
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.6.3. Technology Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. BD
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.7.3. Technology Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. TECHLAB, Inc.
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.8.3. Technology Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. QuidelOrtho Corporation
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.9.3. Technology Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. DiaSorin S.p.A.
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.10.3. Technology Benchmarking
    • 9.4.10.4. Strategic Initiatives
  • 9.4.11. Trinity Biotech
    • 9.4.11.1. Overview
    • 9.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.11.3. Technology Benchmarking
    • 9.4.11.4. Strategic Initiatives
  • 9.4.12. CERTEST BIOTEC
    • 9.4.12.1. Overview
    • 9.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.4.12.3. Technology Benchmarking
    • 9.4.12.4. Strategic Initiatives